

2025

- 02/2025 Vikelis M, Rikos D, Argyriou AA, Dermitzakis EV, Andreou AP & Russo A. *Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis.* Expert Rev Neurother <https://doi.org/10.1080/14737175.2025.2461766> (Ηλεκτρονική διεύθυνση επικοινωνίας: mvikelis@headaches.gr)
- 02/2025 Vikelis M, Kourlaba G, Barba L, Biliak K, Barbalia E, Solakidi A, Trafalis D, Lioliou K, Zyga S, Karapanayiotides T, Mitsikostas DD. *The unmet needs in management, the treatment gap and the burden of migraine in Greece: a Delphi consensus and focus group study from patients' perspective.* Front Neurol. 2025 Feb 24;16:1558014. (Ηλεκτρονική διεύθυνση επικοινωνίας: mvikelis@headaches.gr)
- 02/2025 Kourlaba G, Vikelis M, Karapanayiotides T, Solakidi A, Trafalis D, Lioliou K, Andriopoulos P, Panagiotou A, Mitsikostas DD. *Unmet needs in the management of migraine in Greece from the perspective of medical experts: a Delphi consensus.* Front Neurol. 2025 Feb 12;16:1556808. (Ηλεκτρονική διεύθυνση επικοινωνίας: mvikelis@headaches.gr)
- 04/2025 Gklinos P, Evangelopoulos ME, Velonakis G, Mitsikostas DD. *Migraine and Tension-Type Headache Are Associated with Multiple Sclerosis: A Case-Control Study.* J Clin Med. 2025;14(8):2778. Published 2025 Apr 17. (Ηλεκτρονική διεύθυνση επικοινωνίας: gklinosp@gmail.com)
- 04/2025 Gklinos P, Evangelopoulos ME, Velonakis G, Mitsikostas DD. *Association between multiple sclerosis lesion location, migraine and tension-type headache: A cross-sectional study.* J Clin Neurosci. Published online April 21, 2025. (Ηλεκτρονική διεύθυνση επικοινωνίας: gklinosp@gmail.com)
- 05/2025 Gklinos Panagiotis *Pearls & Oysters: Late-Onset Presumed SUNA in a 91-Year-Old Woman With Headache.* Neurology. 2025;104(9):e213626. (Ηλεκτρονική διεύθυνση επικοινωνίας: gklinosp@gmail.com)
- 06/2025 EV. Dermitzakis, AA. Argyriou, K. Biliak, D. Rikos, G. Xiromerisiou, P. Soldatos, M. Vikelis *The effect of 9-months fremanezumab preventive treatment on the triptan response and on the incidence of triggers and prodromal symptoms in patients with HFEM.* J OF HEADACHE AND PAIN 2025, 26 (Suppl 2):P256 (Ηλεκτρονική διεύθυνση επικοινωνίας: manolis.dermitzakis@gmail.com)

- 06/2025 EV. Dermitzakis, AA. Argyriou, K. Biliias, D. Rikos, G. Xiromerisiou, P. Soldatos, M. Vikelis
Patients' satisfaction to triptans and to available oral and injectable medications (OnabotulinumtoxinA/anti-CGRP MAbs) for migraine prophylaxis. Results of a web-based survey.
J OF HEADACHE AND PAIN 2025, 26 (Suppl 2):P023
(Ηλεκτρονική διεύθυνση επικοινωνίας: manolis.dermitzakis@gmail.com)
- 06/2025 D. Rikos, M. Vikelis, EV. Dermitzakis, P. Soldatos, D. Rallis, J. Rudolf, AP. Andreou, AA. Argyriou
Reporting quality and risk of bias analysis of published RCTs assessing anti-CGRP monoclonal antibodies in migraine prophylaxis – a systematic review.
J OF HEADACHE AND PAIN 2025, 26 (Suppl 2):P029
(Ηλεκτρονική διεύθυνση επικοινωνίας: rikosd@hotmail.com)
- 06/2025 AA. Argyriou, EV. Dermitzakis, G. Xiromerisiou, D. Rikos, D. Rallis, P. Soldatos, P. Litsardopoulos, AP. Andreou, M. Vikelis
Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: Post-hoc analysis of a prospective, real-world Greek registry.
J OF HEADACHE AND PAIN 2025, 26 (Suppl 2):P150
(Ηλεκτρονική διεύθυνση επικοινωνίας: andargyriou@yahoo.gr)
- 06/2025 AA. Argyriou, EV. Dermitzakis, D. Rikos, G. Xiromerisiou, P. Soldatos, P. Litsardopoulos, M. Vikelis
Effects of onabotulinumtoxinA on interictal burden and cutaneous allodynia of patients with chronic migraine.
J OF HEADACHE AND PAIN 2025, 26 (Suppl 2):P146
(Ηλεκτρονική διεύθυνση επικοινωνίας: andargyriou@yahoo.gr)
- 08/2025 Gklinos P, Evangelopoulos ME, Velonakis G, Mitsikostas DD.
Migraine and tension-type headache in multiple sclerosis: A two-year, prospective, longitudinal, controlled study.
Mult Scler Relat Disord. Published online August 5, 2025.
(Ηλεκτρονική διεύθυνση επικοινωνίας: gklinosp@gmail.com)
- 08/2025 AA Argyriou, EV Dermitzakis, G Xiromerisiou, M Chondrogianni, A Foska, P. Soldatos, E Mavraki, D Rikos, P Litsardopoulos, G Tsivgoulis, M Vikelis
Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Data From the GRASP Study Group. Eur J of Neurology. <https://doi.org/10.1111/ene.70327>
(Ηλεκτρονική διεύθυνση επικοινωνίας: andargyriou@yahoo.gr)
- 10/2025 Rees TA, Doukhi D, Wang VS, Balcerbula A, Bravo M, Fathi H, Holmuratova B, Kodounis M, Seyoum SA, Tasdelen S, Vekilyan H, Caronna E, Pozo-Rosich P.
Neck pain in migraine: A narrative review and steps to correct evaluation and treatment.

Cephalalgia. 2025 Oct;45(10):3331024251387449.
(Ηλεκτρονική διεύθυνση επικοινωνίας: kodounis@gmail.com)

- 11/2025 Argyriou AA, Dermitzakis EV, Chondrogianni M, Foska A, Rikos D, Xiomerisiou G, Soldatos P, Litsardopoulos P, Vikelis M on behalf of the Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group.
OnabotulinumtoxinA to Prevent Chronic Migraine with Comorbid Bruxism: Real-World Data from the GRASP Study Group.
Toxins. 2025;17(11):547.
(Ηλεκτρονική διεύθυνση επικοινωνίας: andargyriou@yahoo.gr)
- 12/2025 Argyriou AA, Dermitzakis EV, Chondrogianni M, Foska A, Rikos D, Soldatos P, Vikelis M on behalf of the Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group.
Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study Group.
Journal of Clinical Medicine. 2025; 14(24):8793
(Ηλεκτρονική διεύθυνση επικοινωνίας: andargyriou@yahoo.gr)
- 12/2025 Ζάγκλη Ιωάννα-Ηώ
Νεότερα Δεδομένα στην Αντιμετώπιση της Χρόνιας Κεφαλαλγίας και Ημικρανίας
Περιοδικό Σύγχρονη Ιατρική Ενημέρωση. Δεκέμβριος 2025
(Ηλεκτρονική διεύθυνση επικοινωνίας: iozagkli@yahoo.gr)